Carmustine-releasing wafers for brain metastasis: single institution experience and results of the VIGILANT registry
- 1Department of Neurological Surgery, Wake Forest University School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC 27157 USA
- 2Division of Public Health Sciences, Department of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, NC USA
- 3Department of Radiation Oncology, Wake Forest University School of Medicine, Winston- Salem, NC USA
Abstract
Purpose: Brain metastases affect many patients with solid tumor malignancies. Treatments include surgery, radiation, immunotherapy, and CNS-penetrating chemotherapy. Nonetheless, rates of CNS-related tumor death remain high. Local recurrence after radiosurgery and lesions with a V12 too high for radiosurgery present a particular challenge. The VIGILANT (Vigilant Observation of GLIADEL Wafer Implant) registry prospectively examined use and efficacy of carmustine-releasing wafers which includes patients with brain metastases [1]. Here we present a retrospective analysis of patients with brain metastasis from the VIGILANT registry.
Methods: Forty-seven patients were observed after surgical resection of brain metastasis and GLIADEL implantation at Wake Forest Baptist Medical Center. Thirty-eight patients underwent treatment for local recurrence following radiosurgery. Nine had lesions treated that were deemed too large for successful primary radiosurgery. Patients were evaluated primarily for overall survival (OS) and progression free survival (PFS) from the date of surgery, and secondarily for adverse events and local progression.
Results: Median OS was 23 months. Of 25 deaths, 7 (28%) met criteria for CNS-tumor related etiology. 24 (51.1%) patients had progression during follow up, 6 (12.8%) had local progression. 2 (4.3%) overall had local progression that required additional neurosurgical treatment. Of 9 patients not previously treated with radiosurgery, 4 (44.4%) had no progression. Of 5 patients who received GLIADEL as their upfront cranial intervention, none had local recurrence. 43 patients had adverse events; 2 considered possibly GLIADEL related.
Conclusions: In this single-institution retrospective analysis of prospectively collected registry data, patients undergoing resection and carmustine wafer implantation after prior radiosurgery or for lesions considered unsuitable for primary radiosurgery had favorable observed survival (OS 23 months), intracranial progression (1-year local progression rate of 12%), and minimal related adverse-event outcomes.
Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11060-026-05871-2.
Related
- Acute Ischemic Strokes in Patients With Left Ventricular Non-Compaction Syndrome: A Single Institution Experience and Systematic Literature Review.
- Cytopathologist-Performed Thyroid Fine-Needle Aspiration: An Integrated Single-Institution Experience in Verona.
- Surgical Treatment of Rare Multiple Cardiac Myxomas: A 13-Year Clinical Experience at a Single Institution.
- Patterns of Failure After Postoperative Radiotherapy for WHO Grade 2-3 Meningiomas: A Single-Institution Experience.
- Real-World Clinicopathological Characteristics, Metastatic Distribution, and Treatment Patterns of Triple-Negative Breast Cancer: A Single-Institution Experience from Nigeria
BibTeX
@article{smith2026carmustinereleasing,
title = {{Carmustine-releasing wafers for brain metastasis: single institution experience and results of the VIGILANT registry}},
author = {Eleanor C. Smith and Jared M. Kaplan and Bryan T. Mott and Carol Kittel and Molly Ehrig and Christina K. Cramer and Jaclyn J. White and Stephen B. Tatter},
journal = {Journal of Neuro-Oncology},
year = {2026},
month = nov,
doi = {10.1007/s11060-026-05871-2},
url = {https://doi.org/10.1007/s11060-026-05871-2},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Carmustine-releasing wafers for brain metastasis: single institution experience and results of the VIGILANT registry
AU - Eleanor C. Smith
AU - Jared M. Kaplan
AU - Bryan T. Mott
AU - Carol Kittel
AU - Molly Ehrig
AU - Christina K. Cramer
AU - Jaclyn J. White
AU - Stephen B. Tatter
PY - 2026
DA - 2026/11/11
JO - Journal of Neuro-Oncology
DO - 10.1007/s11060-026-05871-2
UR - https://doi.org/10.1007/s11060-026-05871-2
AB - Purpose: Brain metastases affect many patients with solid tumor malignancies. Treatments include surgery, radiation, immunotherapy, and CNS-penetrating chemotherapy. Nonetheless, rates of CNS-related tumor death remain high. Local recurrence after radiosurgery and lesions with a V12 too high for radiosurgery present a particular challenge. The VIGILANT (Vigilant Observation of GLIADEL Wafer Implant) registry prospectively examined use and efficacy of carmustine-releasing wafers which includes patients with brain metastases [1]. Here we present a retrospective analysis of patients with brain metastasis from the VIGILANT registry. Methods: Forty-seven patients were observed after surgical resection of brain metastasis and GLIADEL implantation at Wake Forest Baptist Medical Center. Thirty-eight patients underwent treatment for local recurrence following radiosurgery. Nine had lesions treated that were deemed too large for successful primary radiosurgery. Patients were evaluated primarily for overall survival (OS) and progression free survival (PFS) from the date of surgery, and secondarily for adverse events and local progression. Results: Median OS was 23 months. Of 25 deaths, 7 (28%) met criteria for CNS-tumor related etiology. 24 (51.1%) patients had progression during follow up, 6 (12.8%) had local progression. 2 (4.3%) overall had local progression that required additional neurosurgical treatment. Of 9 patients not previously treated with radiosurgery, 4 (44.4%) had no progression. Of 5 patients who received GLIADEL as their upfront cranial intervention, none had local recurrence. 43 patients had adverse events; 2 considered possibly GLIADEL related. Conclusions: In this single-institution retrospective analysis of prospectively collected registry data, patients undergoing resection and carmustine wafer implantation after prior radiosurgery or for lesions considered unsuitable for primary radiosurgery had favorable observed survival (OS 23 months), intracranial progression (1-year local progression rate of 12%), and minimal related adverse-event outcomes. Supplementary Information: The online version contains supplementary material available at https://doi.org/10.1007/s11060-026-05871-2.
SN - 0167-594X
SN - 1573-7373
ER -